FAK inhibition has also decreased tumorigenicity in other adult cancers including non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, and bladder cancer [15–18] and in pediatric malignancies including neuroblastoma and Ewing sarcoma [19, 20]. This evidence concerns the gene PTK2 and cancer.